A five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions by unknown
RESEARCH ARTICLE Open Access
A five-gene reverse transcription-PCR assay
for pre-operative classification of breast
fibroepithelial lesions
Wai Jin Tan1, Igor Cima1, Yukti Choudhury1, Xiaona Wei1, Jeffrey Chun Tatt Lim2, Aye Aye Thike2,
Min-Han Tan1* and Puay Hoon Tan2,3*
Abstract
Background: Breast fibroepithelial lesions are biphasic tumors and include fibroadenomas and phyllodes tumors.
Preoperative distinction between fibroadenomas and phyllodes tumors is pivotal to clinical management.
Fibroadenomas are clinically benign while phyllodes tumors are more unpredictable in biological behavior, with
potential for recurrence. Differentiating the tumors may be challenging when they have overlapping clinical and
histological features especially on core biopsies. Current molecular and immunohistochemical techniques have a
limited role in the diagnosis of breast fibroepithelial lesions. We aimed to develop a practical molecular test to aid
in distinguishing fibroadenomas from phyllodes tumors in the pre-operative setting.
Methods: We profiled the transcriptome of a training set of 48 formalin-fixed, paraffin-embedded fibroadenomas
and phyllodes tumors and further designed 43 quantitative polymerase chain reaction (qPCR) assays to verify
differentially expressed genes. Using machine learning to build predictive regression models, we selected a five-gene
transcript set (ABCA8, APOD, CCL19, FN1, and PRAME) to discriminate between fibroadenomas and phyllodes tumors.
We validated our assay in an independent cohort of 230 core biopsies obtained pre-operatively.
Results: Overall, the assay accurately classified 92.6 % of the samples (AUC = 0.948, 95 % CI 0.913–0.983, p = 2.51E-19),
with a sensitivity of 82.9 % and specificity of 94.7 %.
Conclusions: We provide a robust assay for classifying breast fibroepithelial lesions into fibroadenomas and phyllodes
tumors, which could be a valuable tool in assisting pathologists in differential diagnosis of breast fibroepithelial lesions.
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Background
Fibroadenomas and phyllodes tumors are fibroepithelial
lesions of the breast, characterized by proliferation of both
epithelial and stromal components. Fibroadenomas are
more commonly encountered on core biopsies than the
rarer phyllodes tumors (approximately 20 % and <1 %
of breast core needle biopsies respectively) [1, 2]. The
preoperative distinction between the two lesions has
significant impact on subsequent treatment. The current
recommended management for phyllodes tumor diagnosed
on core biopsy is wide excision without axillary staging
regardless of grade [3]. Conversely, fibroadenomas are ob-
served conservatively or, if tumors are larger than 2 cm,
may be simply excised without achieving negative surgical
margins [3]. This approach is due to the indolent behavior
of fibroadenomas, despite sporadic reports of recurrences
[4, 5], while phyllodes tumors have unpredictable outcomes
with malignant tumors potentially progressing to metastasis
and mortality [6–10]. It has been challenging separating
cellular fibroadenoma from benign phyllodes tumor due to
overlapping histological features, and this is particularly
problematic on limited material of core biopsies, which
may lead to over- or under-treatment for some patients,
resulting in unnecessary anxiety and cost.
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Several studies have proposed differentiating histological
features such as stromal cellularity, stromal overgrowth,
fragmentation, subepithelial condensation and presence of
adipose tissue within stroma on core biopsies being indica-
tive of phyllodes tumor [11–13].However, interpretation of
these parameters is subjective, with interobserver variation
and only moderate reproducibility between pathologists
[11, 14]. Varied reports of immunohistochemical markers
used in distinguishing phyllodes tumors from fibroaden-
omas suggest a lack of consensus and objectivity in asses-
sing the expression of these biomarkers. Some authors
reported Ki-67 expression to be helpful in diagnosing phyl-
lodes tumors [15–17] but there are reports to the contrary
[18, 19]. Lin et al. suggested a combination immunoscore
of p16-INK4a and retinoblastoma-associated protein (pRB)
[20] while Maity et al. reported expression of collagen I, III
and CD105-positive microvessel density as parameters to
differentiate the two lesions [21]. The vast majority of these
studies were not conducted using pre-operative biopsies,
which is where key management decision is required.
We set out to identify a useful molecular signature to
help differentiate fibroadenomas from phyllodes tumors
using pre-operative core biopsies to improve prediction
of the final diagnosis.
Methods
Training set for assay development
The study received approval from the Centralized Institu-
tional Review Board (CIRB 2005/002/F). As this was a
retrospective study with anonymized cases, no specific
patient consent was individually required. Forty-eight sam-
ples (24 fibroadenomas and 24 phyllodes tumors) were first
employed as the training set for assay development. These
included 10 paired core biopsies and surgical samples (20
samples), and 28 independent core and excisional samples
from 38 patients (Table 1 and Additional file 1: Table S1).
These formalin-fixed, paraffin-embedded (FFPE) samples
were randomly selected from cases diagnosed at the
Department of Pathology, Singapore General Hospital
from 2008 to 2012. Hematoxylin and eosin (H&E)-stained
slides were retrieved and reviewed. Phyllodes tumor was
defined when there were well-developed fronds accompan-
ied by increased stromal cellularity as opposed to fibro-
adenomas in which epithelial and stromal components
were arranged in either intracanalicular or pericanalicular
patterns without fronds or stromal hypercellularity.
Differences in clinical features between fibroadenomas
and phyllodes tumors were assessed with Mann–Whitney
U test and Fisher’s exact test.
Expression profiling by Whole-Genome DASL® High
Throughput (HT) Assay
Representative tumor areas were identified of which
three to seven sections of 10-μm-thick sections from the
same FFPE tumor block were obtained, deparaffinized
and macrodissected. RNA was extracted using the
RNeasy FFPE kit (Qiagen, Hilden, Germany) and quanti-
fied by Nanodrop Spectrophotometer (Thermo Fisher
Scientific, Waltham, MA, USA). A total of 100 ng was
used for quality assessment by real-time amplification of
the RPL13A gene (forward primer, 5’-CACTTGGGGA-
CAGCATGAG-3’, and reverse primer, 5’-GTAACCCCT
TGGTTGTGCAT-3’) using the Power SYBR® Green
RNA-to-CT™ 1-Step Kit (Life Technologies, Carlsbad,
CA, USA) on a CFX96™ Real-Time PCR instrument
(Bio-Rad Laboratories, Hercules, CA, USA). Samples
with threshold cycle (Ct) below 29 were further sub-
jected to quality assessment on a bioanalyzer. Eligible
samples were submitted for expression profiling on the
Whole-Genome DASL® HT Assay (Illumina, Inc., San
Diego, CA, USA) at the Biopolis Shared Facilities A*Star,
Singapore. The assay interrogates 29,377 features using
the HumanHT-12 v4 BeadChip (Illumina, Inc.). Quantile-
normalized gene expression data pre-analyzed using
GenomeStudio® (Illumina, Inc.) was delivered. Data are
available through GEO [GEO: GSE78071].
Selection of normalization genes and differentiating genes
Normalization genes were selected based on the smallest
value of coefficient of variation among all samples. Dif-
ferentiating genes were selected using the Significance
Analysis of Microarrays package [22] and filtered based
on the following criteria: (1) q-value less than 0.05; (2)
mean difference of expression above 500; (3) R-fold




tumors (n = 19)
p value
Age
Median (range) 35 (17–80) 44 (18–64) 0.09
Size
Median (range) 25 (15–50) 65 (25–220) < 0.001
Ethnicity, n (%) 0.2
Chinese 13 (68.4) 11 (57.9)
Malay 0 (0.0) 4 (21.0)
Indian 2 (10.5) 1 (5.3)




Benign phyllodes tumor 13b
Borderline phyllodes tumor 3c
Malignant phyllodes tumor 3c
aFour paired core biopsies and surgical excisions
bThree paired core biopsies and surgical excisions
cOne paired core biopsy and surgical excision
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above 1.5 (for genes highly expressed in phyllodes
tumors) or less than 0.67 (for genes highly expressed
in fibroadenomas).
Design of quantitative polymerase chain reaction (qPCR)
assay
cDNA was synthesized from 1 μg of RNA using the
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems®, Life Technologies, Carlsbad, CA, USA).
Each qPCR assay consisted of 1X Power SYBR® Green
PCR Master Mix (Life Technologies), 0.5 μM of forward
and reverse primer each and 1 μl of 10-fold diluted
cDNA as a template in a final total volume of 10 μl.
Primers were designed using Primer-BLAST (NCBI, Be-
thesda, MD, USA) [23] with accession number listed in
Additional file 1: Table S2. Non-template control acted
as a negative control. Specificity of the amplicons was
verified by melt curve analysis.
Data quantification and model building
Delta Ct (ΔCt) for each gene and sample was quantified as:
ΔCt =Ct(gene, sample) − geomean(Ct(five normalization
gene)). For comparison with expression of the Whole-
Genome DASL® HT Assay, ΔCt data was transformed
to 2-ΔCt as a positive linear scale and significance of
correlation was analyzed with Pearson’s correlation
test. Similarly to Cima et al. and Kälin et al. [24, 25],
we used Random Forest (RF) ensemble classifier [26]
to rank the importance of gene transcripts differentiating
fibroadenomas and phyllodes tumors on qPCR assays.
The top seven performing genes were used to build pre-
dictive logistic regression models using exhaustive search
for the best model. To this end we used the glmulti
package [27] with inclusion of the interaction terms. The
best model was selected based on the lowest Akaike infor-
mation criteria (AIC) value [28].
Validation cohort for model validation
The model of the multigene assay was tested on a separ-
ate set of 230 core biopsies with at least 2 years of
follow-up. Hematoxylin and eosin (H&E)-stained slides
were retrieved and reviewed. The outcome of the multi-
gene assay was compared against the final diagnosis on
the corresponding surgical excisions. Cases without sub-
sequent surgical excisions were free from progression
for at least 2 years and diagnosis made based on the ini-
tial core biopsy was used as the reference instead.
Results
Clinical features of training set
The clinical features and histology of the training set are
shown in Table 1. Examples of the histological appear-
ances of fibroadenoma and phyllodes tumor are shown
in Fig. 1. Phyllodes tumors were significantly larger than
fibroadenomas (p < 0.001). Median age of patients diag-
nosed with fibroadenomas and phyllodes tumors was
35 years and 44 years respectively (p = 0.09). No signifi-
cant differences were observed for ethnicity distribution
between the two groups of tumors.
Expression profiling and correlation with qPCR assays
Forty-seven samples (97.9 %) from 37 patients passed the
quality control and were profiled successfully. Genes
discriminating fibroadenomas and phyllodes tumors are
listed in Additional file 1: Table S3. We designed and vali-
dated qPCR assays on 43 selected genes. Concordance
Fig. 1 Histology of fibroadenoma and phyllodes tumor on surgical excisions. a, b An example of a fibroadenoma at low-power (a) and high-power
(b) magnifications. c, d An example of a benign phyllodes tumor at low-power (c) and high-power (d) magnifications
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between expression profiling and the qPCR assays
was assessed based on a pilot run on six representative
samples (Additional file 1: Table S4). Twenty-three assays
with Pearson’s r of above 0.6 were further tested on the
remaining 40 samples. One case was excluded due to in-
sufficient material after expression profiling.
Development of a multigene qPCR panel
The results of ΔCt for all 23 qPCR assays were ranked
using variable importance feature of the Random Forest
classifier (Fig. 2). The seven most important genes in
separating fibroadenomas and phyllodes tumors were
TRIM29, FN1, CCL19, ABCA8, NPTX2, APOD and
PRAME. A total of 268,435,456 candidate models were
identified by glmulti based on these seven genes. We
employed the genetic algorithm approach in the package
to perform automated screening for the best model based
on AIC value. A final five-gene model encompassing
APOD, ABCA8, PRAME, FN1, and CCL19 with AIC of
14.2 was returned with coefficients as listed in Table 2.
Performance of the model
Patient demographics of the validation cohort of 230
core biopsies are shown in Table 3. Overall the assay
was able to predict 213 (92.6 %) cases accurately. The
prediction accuracy rates for fibroadenomas and phyl-
lodes tumors were 94.7 % (179/189) and 82.9 % (34/41)
respectively (Table 4), with positive (PPV) and negative
(NPV) predictive values of 77.3 % and 96.2 %. A receiver
operating characteristics curve with an area under the
curve (AUC) of 0.948 (95 % confidence interval (CI)
0.913–0.983, p = 2.51E-19) was generated, indicating a
large effect size in expected diagnostic performance for
the five-gene assay (Fig. 3).
Of the 17 discordant cases (Table 5), seven were diag-
nosed as phyllodes tumors on pathological reports but
were predicted as fibroadenomas on our assay. Upon re-
view of these seven cases, two cases contained high epi-
thelium content (Fig. 4), two were heterogeneous on
histology with focal areas suggestive of fibroadenomas,
while three other cases were confirmed as phyllodes tu-
mors on review. The other ten of the 17 discordant cases
were diagnosed as fibroadenomas on pathological re-
ports but were predicted as phyllodes tumors on our
assay. Among these ten cases, six cases had post-
operative excisional material available as reference while
the remaining four cases were benchmarked against the
pre-operative pathological diagnosis. Of the six with ex-
cisional material, four were unequivocally fibroadenomas
on histology, one was a cellular fibroadenoma without
prominent fronds, and one was a fibroadenoma with
sclerosing adenosis. Of the four pre-operative biopsies,
one was unequivocally fibroadenoma, two cases con-
tained features in keeping with fibroadenoma with hyali-
nized leafy fronds noted albeit without stromal
cellularity, and one was an indeterminate case with focal
areas of hemorrhage and high cellularity, which could
not be definitively concluded on review.
Fig. 2 Box plot of mean decrease in accuracy for 100 Random
Forest trees generated for each gene. Mean decrease in accuracy
measures the importance of each gene to the classification
Table 2 Coefficients of the best model in predicting diagnosis






Table 3 Patient demographics of the validation cohort of 230
core biopsies











with subsequent surgical excisions 58 25.2
without subsequent surgical excisions 131 57
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Among the 230 core biopsies, the pre-operative patho-
logical diagnoses were inconclusive for 22 cases where
the term ‘fibroepithelial lesion’ was assigned, and there
were three cases where the preoperative diagnoses were
incongruous with the post-operative outcome (Table 6).
Of these 25 cases, the five-gene assay was 80 % (20/25)
accurate in classification with a PPV of 94.7 %.
Discussion
Classification of breast fibroepithelial tumors based on
differentiating morphological and immunohistochemical
features on pre-operative material has been challenging
with variable findings across different groups (see Table 7
for summary). Jacobs et al. and Lee et al. first described
individual pathological parameters which might help to
differentiate fibroadenomas and phyllodes tumors in
these limited samples [11, 16]. Jara-Lazaro proposed a
combination of histological and immunohistochemical
markers to indicate phyllodes tumors on core biopsies
[15] but did not weigh the relative importance of each
parameter in predicting phyllodes tumors. Morgan
addressed this question by proposing a predictive
tool including coefficient factors for each parameter
to distinguish between fibroadenomas and phyllodes tu-
mors but this has yet to be validated in an independent
series of core biopsies [12]. Our study is the first to inves-
tigate differentiating features of fibroepithelial lesions on
pre-operative material at the molecular level. We have de-
veloped a five-gene assay using a systematic approach
based on genome-wide expression profiling data and
validated the assay in an independent cohort of 230
pre-operative core biopsies of breast fibroepithelial le-
sions, the largest cohort reported so far. The pre-operative
core biopsies were FFPE tissue containing low-quality
RNA. Accordingly, our assay has been developed using
RNA extracted from limited FFPE materials from core bi-
opsies and thus is expected to perform on such material
in the clinical setting.
Comparatively in surgical excisional materials, Huang
et al. proposed a two-gene test derived from methylation
profiling of an 11-gene panel in 86 samples [29], which
described an elevated RASSF1A and/or TWIST1 methy-
lation observed in phyllodes tumors as compared to
fibroadenomas. They further evaluated the test in a sep-
arate validation cohort of 19 samples and reported a
sensitivity and specificity of 0.33 and 0.75 respectively,
Table 4 Performance of the five-gene model in predicting
diagnosis in the independent validation cohort of 230 core biopsies





Fibroadenomas 179 7 NPV = 0.962
Phyllodes tumors 10 34 PPV = 0.773
Spec = 0.947 Sen = 0.829
The five-gene assay has an overall accuracy of 92.6 %, with a sensitivity (sen)
of 82.9 % and specificity (spec) of 94.7 %. The positive predictive value (PPV)
and negative predictive value (NPV) are 77.3 % and 96.2 % respectively
Fig. 3 Receiver operating characteristics (ROC) curve of the five-gene
model with an area under the curve (AUC) of 0.948 (95 % confidence
interval (CI) 0.913–0.983, p = 2.51E-19) in predicting diagnosis in the
independent set of 230 core biopsies
Table 5 Seventeen cases with discordant outcomes between
the five-gene assay and pathological diagnosis in the validation
cohort. Post-operative diagnoses were used as benchmark
reference unless otherwise stated
Sample ID Five-gene assay Pathological diagnosis
CB22 FA Benign PTa
CB116 FA Benign PT
CB95 FA Benign PT
CB28 FA Benign PTa
CB68 FA Benign PTa
CB120 FA Borderline PTa
CB130 FA Borderline PT










FA fibroadenoma, PT phyllodes tumor
aPre-operative pathological diagnoses were inconclusive or discordant with
post-operative pathological diagnoses (see Table 6 asterisked cases)
bCases of core biopsies without subsequent surgical excisions. Outcome of the
five-gene assay was benchmarked against the pre-operative
pathological diagnosis
cFeatures in keeping with fibroadenoma with hyalinized leafy fronds noted
albeit without stromal cellularity
dFocal areas of hemorrhage and high cellularity, diagnosis could not be
definitively concluded on review
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with a PPV and NPV of 0.83 and 0.23. However, devel-
opment of the test from a pre-selected panel of 11 genes
may not be representative and the sample size of the
validation cohort was too small to be conclusive. In
contrast, our assay has a better sensitivity and specifi-
city at 0.83 and 0.95 despite a lower PPV of 0.77. In
a separate study by Kuijper interrogating the transcrip-
tome differences between five fibroadenomas and eight
phyllodes tumors, CTAG1/2, PRAME, HOXC13, ELF5 and
FABP7 were among 96 other transcripts found to be
highly differentially expressed between fibroadenomas and
phyllodes tumors [30]. More recently, Vidal et al. reported
a cluster of 47 epithelial- and luminal-related genes was
found to be more expressed in fibroadenomas than phyl-
lodes tumors among 105 breast cancer-related genes stud-
ied [31]. Findings from these studies however, were not
further deployed as a test to distinguish fibroadenomas
from phyllodes tumors on pre-operative materials despite
the significant differential expression observed.
The training cohort comprised a mixture of surgical
excisions and core biopsies with varying classifications of
fibroepithelial lesions, simulating a realistic clinical sce-
nario. Phyllodes tumors comprise benign, borderline and
malignant grades on a continuous spectrum [32]. It is
important that the assay works across the spectrum
although one may argue that the malignant grade of
phyllodes tumors is rarely in the histologic differential
diagnosis between fibroadenomas and phyllodes tumors,
and hence the assay may have little utility in the separ-
ation of fibroadenomas from malignant phyllodes tumors.
The proportion of malignant phyllodes tumors included
in the training cohort concurs with the incidence of malig-
nant phyllodes tumors reported in the literature [33].
Nevertheless, even with the exclusion of malignant
phyllodes tumors in the training cohort, differences of
expression between fibroadenomas and phyllodes tumors
for genes selected for the assay still fall within our se-
lection criteria (R-fold differences above 1.5 and mean
differences above 500) and hence would not have
altered the assay development outcome. Excluding the
Fig. 4 Example of a discordant case containing high epithelium content. The five-gene assay predicted the core biopsies (a) as fibroadenoma but
the final surgical excision (b) was diagnosed as phyllodes tumor on pathological reports
Table 6 Cases with inconclusive pre-operative pathological
diagnoses (n = 22), and discordant pre-and post-operative
pathological diagnoses (n = 3). Among these cases, the five-gene
assay was 80 % (20/25) accurate in predicting the final
post-operative outcome
Sample ID Pathological reports Outcome from
five-gene assayPre-operative Post-operative
CB22 FA Benign PT FAa
CB36 FA Benign PT PT
CB111 FA Benign PT PT
CB21 FEL Benign PT PT
CB31 FEL Benign PT PT
CB40 FEL Benign PT PT
CB43 FEL Benign PT PT
CB57 FEL Benign PT PT
CB59 FEL Benign PT PT
CB96 FEL Benign PT PT
CB99 FEL Benign PT PT
CB107 FEL Benign PT PT
CB114 FEL Benign PT PT
CB20 FEL Borderline PT PT
CB42 FEL Borderline PT PT
CB55 FEL Borderline PT PT
CB73 FEL Borderline PT PT
CB78 FEL Borderline PT PT
CB101 FEL Borderline PT PT
CB115 FEL Borderline PT PT
CB122 FEL Borderline PT PT
CB28 FEL Benign PT FAa
CB68 FEL Benign PT FAa
CB120 FEL Borderline PT FAa
CB77 FEL FA PTa
FA fibroadenoma, PT phyllodes tumor, FEL fibroepithelial lesion without
definitive assignment into fibroadenoma or phyllodes tumor
aInaccurate classification by the five-gene assay benchmarked against the
post-operative pathological diagnosis
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three malignant tumor cases in the validation cohort
only slightly reduces the sensitivity and PPV from
0.829 and 0.773 to 0.816 and 0.756 respectively. It is
not our aim to investigate the differential expression
between the phyllodes tumor grades although there is
a trend of differences observed between grades in the
expression of these five genes (results not shown).
The sample sizes of borderline and malignant phyllodes
tumors would be too small for meaningful analysis.
Several underlying factors which potentially limit the
performance of the assay resulting in 17 discordant out-
comes between the assay and pathological diagnosis in-
clude tumor heterogeneity and the issue of sampling on
core biopsies. These factors may also have contributed
to the three discordant pathological diagnoses between
pre-operative core and post-operative excision materials.
Core biopsies offer insight into only part of a tumor,
which may not truly represent its entirety. Also, it is not
uncommon for phyllodes tumors to contain areas indis-
tinguishable from fibroadenomas, as seen in two dis-
cordant phyllodes tumor cases incorporating focal areas
suggestive of fibroadenomas. Two other discordant phyl-
lodes tumors harbored high epithelium content. The con-
tribution of the epithelial component to the performance
of the assay has yet to be ascertained although previous
studies have shown that mutations were found in the stro-
mal but not epithelial component [34, 35].
The limitation of our validation cohort is that the
sample size for phyllodes tumor is small but the test
was validated on a larger number of fibroadenomas, which
have higher incidence compared to phyllodes tumors. We
incorporated fibroadenomas on core biopsies which were
not excised surgically although these may theoretically in-
clude uncertainty as the diagnoses are based solely on the
core biopsy and not on the excised tumor. However, pre-
cluding fibroadenomas without subsequent excisions
would result in a selection bias due to the exclusion of a
large portion of representative cases. Moreover, the inci-
dence of phyllodes tumor subsequent to a fibroadenoma
diagnosis on core biopsy is very low [36], with an average
duration of 12 months to the final correct diagnosis.
We do not advocate that the current diagnostic frame-
work be replaced by the assay. Apart from the histo-
logical findings, clinical decision whether to proceed
with surgical excision takes into account other factors
such as radiological size and characteristics, as well as
patient symptoms. For instance, a diagnosis of fibro-
adenoma on core biopsy may still be followed by exci-
sion if there is radiologic-pathologic discordance, or if
the lesion is large or symptomatic. A diagnosis of phyl-
lodes tumor on core biopsy however, warrants excision.
Incorporating the results from our assay allows an add-
itional tool that can be integrated into the decision-
making process, enhancing precision especially when it
affirms the pathological assessment on core biopsy. The
gene assay is also helpful for pathologists in interpreting
these lesions when the histological characteristics are in-
determinate or ambiguous. This is exemplified by the 22
fibroepithelial lesions without a conclusive classification
on core biopsy in the validation cohort. The multigene
assay was able to classify 82 % of these cases accurately
with a PPV of 94.7 %. The practicality and utility of the
assay however, will need to be further validated in pro-
spective studies.
Table 7 Summary of selected studies investigating differential features of fibroadenomas and phyllodes tumors on pre-operative
materials
Author N Assessment approach Key findings




Stromal cellularity, mitoses, expression of Ki-67 and
topoisomerase IIα might help determining phyllodes tumors
Lee [11] 38 FAs44 PTs Histology Features indicating phyllodes tumors:
(1) increased stromal cellularity in at least 50 % of the specimen;
(2) stromal overgrowth; (3)fragmentation and; 4) presence of
adipose tissue within stroma




(1) Marked stromal hypercellularity and nuclear atypia, stromal
overgrowth, and ill-defined lesional margins exclusively predicted
phyllodes tumor on excision.
(2) Expression of Ki67 ≥ 5 %, topoisomerase IIα ≥ 5% and
reduced CD34 correlates significantly with phyllodes tumors.
Morgan [12] 91a FAs
21 PTs
Histology Proposed two putative predictive tools:
(1) Logit P(x) = − 0.9014 (age) − 3.61 (mitosis) + 11.156
(2) Z = 0.8909(age) + 0.0347(% stroma) + 0.5274 (mitoses/10HPF)
Yasir [13] 37 FAs
27 PTs
Histology Stromal mitoses and/or three or more histological features were
helpful in predicting phyllodes tumors on excisions.
FAs fibroadenomas, PTs phyllodes tumors
aDiagnoses not confirmed on excisions
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The five-gene assay includes genes of various biological
functions. FN1 (fibronectin 1) encodes a major compo-
nent of the extracellular matrix. APOD (apolipoprotein D)
and ABCA8 (ATP-binding cassette, sub-family A
member 8) encode transporter proteins while PRAME
(preferentially expressed antigen in melanoma) and
CCL19 (chemokine ligand 19) genes are involved in
immunoregulatory processes. Some of these genes
were reported to be useful in differential diagnosis of
other forms of tumors such as FN1 as a marker for
renal cell carcinoma aggressiveness [37], PRAME as a
marker for differentiating Müllerian carcinoma from
malignant mesothelioma [38] and ABCA8 as part of a
multigene gene assay for classifying cancer types [39].
While the individual functional role of these genes has not
been implicated in breast fibroepithelial lesions, we found
that these markers work best in combination for dif-
ferential diagnosis between fibroadenomas and phyl-
lodes tumors, as derived from our model algorithm.
Nonetheless, it would be of interest to investigate the
functional roles of these genes in breast fibroepithelial
lesions in future studies.
Conclusions
We have developed a practical molecular assay for
fibroepithelial lesions, classifying fibroadenomas and
phyllodes tumors in pre-operative core biopsies. This
may serve as an adjunctive aid for accurate pathological
diagnosis. Prospective real-world trials will be helpful to
determine whether improved surgical decision-making,
supported by more accurate histological diagnosis, will
lead to better outcomes.
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Additional file 1: Supplementary tables. Table S1 Details of 48
samples from 38 patients constituting the training cohort. Table S2
Primers designed for potential differentiating genes and normalization
genes. Table S3 Significant genes differentially expressed between
fibroadenomas (FAs) and phyllodes tumors (PTs). Table S4 Correlation
between expression profiling and qPCR assays based on a pilot run of six
representative samples. Genes with good correlation value (r ≥ 0.6) were
subjected to testing on remaining 40 samples. (XLSX 59 kb)
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